Similar articles

• Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.

  Iwamoto J, Seki A, Takeda T, Yamada H, Sato Y, Yeh JK. Iwamoto J, et al. Chin J Physiol. 2008 Jun 30;51(3):121-8. Chin J Physiol. 2008. Retraction in: Chin J Physiol. 2019 Mar-Apr;62(2):93. doi: 10.4103/0304-4920.188613. PMID: 18935906 Retracted.
• Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.

  Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Iwamoto J, et al. Exp Anim. 2006 Jul;55(4):357-67. doi: 10.1538/expanim.55.357. Exp Anim. 2006. Retraction in: Exp Anim. 2018;67(3):R2. doi: 10.1538/expanim.55.357.r1. PMID: 16880683 Retracted.
• Retraction: Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.

  Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Iwamoto J, et al. Exp Anim. 2018;67(3):R1. doi: 10.1538/expanim.55.333.r1. Exp Anim. 2018. PMID: 30058617 Free PMC article.
• Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.

  Iwamoto J, Matsumoto H, Takeda T, Sato Y, Liu X, Yeh JK. Iwamoto J, et al. Calcif Tissue Int. 2008 Aug;83(2):121-8. doi: 10.1007/s00223-008-9146-1. Epub 2008 Jun 10. Calcif Tissue Int. 2008. PMID: 18543014
• Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.

  Dunn CJ, Goa KL. Dunn CJ, et al. Drugs. 2001;61(5):685-712. doi: 10.2165/00003495-200161050-00013. Drugs. 2001. PMID: 11368289 Review.